CA2388995A1 - Nouveau procede - Google Patents
Nouveau procede Download PDFInfo
- Publication number
- CA2388995A1 CA2388995A1 CA002388995A CA2388995A CA2388995A1 CA 2388995 A1 CA2388995 A1 CA 2388995A1 CA 002388995 A CA002388995 A CA 002388995A CA 2388995 A CA2388995 A CA 2388995A CA 2388995 A1 CA2388995 A1 CA 2388995A1
- Authority
- CA
- Canada
- Prior art keywords
- vaccine
- polysaccharide
- dose
- infant
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 48
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 136
- 239000005017 polysaccharide Substances 0.000 claims abstract description 136
- 150000004676 glycans Chemical class 0.000 claims abstract description 125
- 229960005486 vaccine Drugs 0.000 claims abstract description 80
- 241001465754 Metazoa Species 0.000 claims abstract description 45
- 230000004044 response Effects 0.000 claims abstract description 39
- 108010060123 Conjugate Vaccines Proteins 0.000 claims abstract description 30
- 229940031670 conjugate vaccine Drugs 0.000 claims abstract description 30
- 241000282412 Homo Species 0.000 claims abstract description 27
- 230000028993 immune response Effects 0.000 claims abstract description 17
- 231100000673 dose–response relationship Toxicity 0.000 claims abstract description 16
- 230000001580 bacterial effect Effects 0.000 claims abstract description 15
- 210000002966 serum Anatomy 0.000 claims abstract description 11
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract description 10
- 108010078791 Carrier Proteins Proteins 0.000 claims abstract description 10
- 238000012360 testing method Methods 0.000 claims abstract description 10
- 230000002163 immunogen Effects 0.000 claims abstract description 9
- 239000000427 antigen Substances 0.000 claims description 35
- 102000036639 antigens Human genes 0.000 claims description 35
- 108091007433 antigens Proteins 0.000 claims description 35
- 229940001442 combination vaccine Drugs 0.000 claims description 15
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 claims description 11
- 101710188053 Protein D Proteins 0.000 claims description 11
- 101710132893 Resolvase Proteins 0.000 claims description 11
- 238000002965 ELISA Methods 0.000 claims description 8
- 241000606768 Haemophilus influenzae Species 0.000 claims description 6
- 238000011081 inoculation Methods 0.000 claims description 6
- 230000005875 antibody response Effects 0.000 claims description 5
- 241001505901 Streptococcus sp. 'group A' Species 0.000 claims description 4
- 241000193990 Streptococcus sp. 'group B' Species 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims description 3
- 101000597577 Gluconacetobacter diazotrophicus (strain ATCC 49037 / DSM 5601 / CCUG 37298 / CIP 103539 / LMG 7603 / PAl5) Outer membrane protein Proteins 0.000 claims description 3
- 101710183389 Pneumolysin Proteins 0.000 claims description 3
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 3
- 229960003983 diphtheria toxoid Drugs 0.000 claims description 3
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 3
- 229960000814 tetanus toxoid Drugs 0.000 claims description 3
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims description 2
- 208000035109 Pneumococcal Infections Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000010171 animal model Methods 0.000 abstract description 20
- 238000003306 harvesting Methods 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 30
- 238000002347 injection Methods 0.000 description 25
- 239000007924 injection Substances 0.000 description 25
- 239000002671 adjuvant Substances 0.000 description 14
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 11
- 229940001007 aluminium phosphate Drugs 0.000 description 11
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 239000000203 mixture Substances 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 241000700112 Chinchilla Species 0.000 description 4
- 241000282560 Macaca mulatta Species 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000000625 opsonophagocytic effect Effects 0.000 description 3
- 229940031999 pneumococcal conjugate vaccine Drugs 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000003497 anti-pneumococcal effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000001662 opsonic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229940031351 tetravalent vaccine Drugs 0.000 description 2
- 241000700198 Cavia Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940031937 polysaccharide vaccine Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000012429 release testing Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La présente invention a trait au domaine des procédés permettant de tester une réponse à un vaccin chez un modèle animal, afin d'obtenir des informations concernant la réponse d'êtres humains au même vaccin. Cette invention concerne un procédé permettant de déterminer la dose-réponse d'un être humain à un vaccin conjugué, à base de polysaccharide, comprenant une protéine support immunogène et un polysaccharide bactérien. Ce procédé consiste à administrer à un animal en bas âge une dose dudit vaccin conjugué, à déterminer la réponse immunitaire de l'animal au polysaccharide bactérien, en tant que mesure de la réponse immunitaire d'un être humain. Des modes de réalisation préférés de cette invention concernent des modes d'administration de vaccin chez le modèle, la dose de vaccin testé, l'intervalle de temps entre les doses, le temps de récolte de sérum, un procédé de détermination de réponse immunitaire et le type (et l'âge) d'animal en bas âge utilisé.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9925559.8 | 1999-10-28 | ||
| GBGB9925559.8A GB9925559D0 (en) | 1999-10-28 | 1999-10-28 | Novel method |
| PCT/EP2000/010733 WO2001030390A2 (fr) | 1999-10-28 | 2000-10-27 | Nouveau procede |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2388995A1 true CA2388995A1 (fr) | 2001-05-03 |
Family
ID=10863574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002388995A Abandoned CA2388995A1 (fr) | 1999-10-28 | 2000-10-27 | Nouveau procede |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1223987A2 (fr) |
| JP (1) | JP2003512440A (fr) |
| AU (1) | AU1854901A (fr) |
| CA (1) | CA2388995A1 (fr) |
| GB (1) | GB9925559D0 (fr) |
| WO (1) | WO2001030390A2 (fr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20024224A3 (cs) * | 2000-06-29 | 2003-05-14 | Glaxosmithkline Biologicals S. A. | Farmaceutický prostředek |
| JP2005504718A (ja) | 2001-01-23 | 2005-02-17 | アヴェンティス パストゥール | 多価髄膜炎菌多糖−タンパク質複合ワクチン |
| GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| GB0211118D0 (en) * | 2002-05-15 | 2002-06-26 | Polonelli Luciano | Vaccines |
| DE60335477D1 (de) | 2002-10-11 | 2011-02-03 | Novartis Vaccines & Diagnostic | Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien |
| GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| PT2172213E (pt) | 2003-01-30 | 2013-06-03 | Novartis Ag | Vacinas injetáveis contra múltiplos serogrupos meningocócicos |
| ATE506963T1 (de) | 2003-10-02 | 2011-05-15 | Novartis Vaccines & Diagnostic | Kombinationsimpfstoffe gegen meningitis |
| GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
| EP2460813A1 (fr) | 2003-12-17 | 2012-06-06 | Janssen Alzheimer Immunotherapy | Conjugués transporteurs de peptides bêta immunogènes et leurs procédés de production |
| PL2878307T3 (pl) | 2005-06-27 | 2020-01-31 | Glaxosmithkline Biologicals S.A. | Kompozycja immunogenna |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| CA2646993C (fr) | 2006-03-22 | 2016-01-26 | Novartis Ag | Schema posologique pour une immunisation avec des conjugues de meningocoques |
| US10828361B2 (en) | 2006-03-22 | 2020-11-10 | Glaxosmithkline Biologicals Sa | Regimens for immunisation with meningococcal conjugates |
| CN103357003A (zh) | 2006-09-07 | 2013-10-23 | 葛兰素史密丝克莱恩生物有限公司 | 疫苗 |
| US20100074918A1 (en) | 2007-05-02 | 2010-03-25 | Jan Poolman | Vaccine |
| GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
| NZ584683A (en) | 2007-10-19 | 2012-05-25 | Novartis Ag | Neisseria meningitidis serogroup B vaccine formulations |
| US9579372B2 (en) | 2008-02-21 | 2017-02-28 | Glaxosmithkline Biologicals Sa | Meningococcal fHBP polypeptides |
| BRPI0923006A2 (pt) | 2008-12-17 | 2016-03-08 | Novartis Ag | vacinas meningococicas incluindo receptor de hemoglobina |
| BRPI1009829A2 (pt) | 2009-03-24 | 2016-11-16 | Novartis Ag | combinações de proteína de ligação de fator h meningocócico e conjugados de sacarídeos pneumocócicos |
| BR112012004275A2 (pt) | 2009-08-27 | 2016-11-16 | Novartis Ag | polipeptídios híbridos incluindo sequências meningocócicas de fhbp |
| WO2011039631A2 (fr) | 2009-09-30 | 2011-04-07 | Novartis Ag | Expression de polypeptides fhbp méningococciques |
| EP2493499A1 (fr) | 2009-10-27 | 2012-09-05 | Novartis AG | Polypeptides fhbp méningococciques modifiés |
| AU2011300418B2 (en) | 2010-09-10 | 2016-05-12 | Glaxosmithkline Biologicals Sa | Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom |
| WO2012153302A1 (fr) | 2011-05-12 | 2012-11-15 | Novartis Ag | Antipyrétiques pour améliorer la tolérabilité de vaccins à base de vésicules |
| CN102507924B (zh) * | 2011-11-17 | 2014-06-18 | 成都欧林生物科技股份有限公司 | 检测发酵液多糖浓度的方法 |
| MX2014008988A (es) | 2012-02-02 | 2014-08-27 | Novartis Ag | Promotores para aumento de expresion de proteinas en meningococo. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604108A (en) * | 1992-09-14 | 1997-02-18 | Connaught Laboratories, Inc. | Test for determining the dose response of a conjugated vaccine |
| GB9727262D0 (en) * | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
| EP1162999B1 (fr) * | 1999-03-19 | 2006-11-29 | Glaxosmithkline Biologicals S.A. | Vaccin contre Streptococcus pneumoniae |
-
1999
- 1999-10-28 GB GBGB9925559.8A patent/GB9925559D0/en not_active Ceased
-
2000
- 2000-10-27 EP EP00981226A patent/EP1223987A2/fr not_active Withdrawn
- 2000-10-27 JP JP2001532807A patent/JP2003512440A/ja active Pending
- 2000-10-27 WO PCT/EP2000/010733 patent/WO2001030390A2/fr not_active Ceased
- 2000-10-27 AU AU18549/01A patent/AU1854901A/en not_active Abandoned
- 2000-10-27 CA CA002388995A patent/CA2388995A1/fr not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| GB9925559D0 (en) | 1999-12-29 |
| AU1854901A (en) | 2001-05-08 |
| EP1223987A2 (fr) | 2002-07-24 |
| WO2001030390A2 (fr) | 2001-05-03 |
| JP2003512440A (ja) | 2003-04-02 |
| WO2001030390A3 (fr) | 2002-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2388995A1 (fr) | Nouveau procede | |
| Lesinski et al. | Vaccines against polysaccharide antigens | |
| Shelly et al. | Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults | |
| JP4162267B2 (ja) | Ｎｅｉｓｓｅｒｉａ ｍｅｎｉｎｇｉｔｉｄｉｓ血清型Ｂ複合糖質およびその使用法 | |
| JP3989951B2 (ja) | 組み合わせ髄膜炎ワクチン | |
| TWI477283B (zh) | 免疫原組合物 | |
| Käyhty et al. | Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children | |
| US6224880B1 (en) | Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines | |
| Anttila et al. | Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood | |
| Soininen et al. | IgG subclass distribution of antibodies after vaccination of adults with pneumococcal conjugate vaccines | |
| Alexander et al. | Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE®) | |
| US20220118072A1 (en) | Neisseria meningitidis compositions and methods thereof | |
| US6413520B1 (en) | Methods of immunizing adults using anti-meningococcal vaccine compositions | |
| US20040191834A1 (en) | Novel method | |
| Simell et al. | Pneumococcal carriage and acute otitis media induce serum antibodies to pneumococcal surface proteins CbpA and PhtD in children | |
| Simonsen et al. | Immunogenicity of a 23-valent pneumococcal polysaccharide vaccine in Brazilian elderly | |
| Koskela et al. | Enzyme immunoassay for detection of immunoglobulin G (IgG), IgM, and IgA antibodies against type 6B pneumococcal capsular polysaccharide and cell wall C polysaccharide in chinchilla serum | |
| Bonilla | Vaccination of immune-deficient patients | |
| Vella et al. | Biological activity of Hib conjugates | |
| US20220387614A1 (en) | Dosage and administration of a bacterial saccharide glycoconjugate vaccine | |
| Scheifele et al. | Evaluation of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) in Canadian infants | |
| DE LA SANTE | RECOMMENDATIONS FOR THE PRODUCTION & CONTROL OF PNEUMOCOCCAL CONJUGATE VACCINES | |
| Dolan et al. | An enzyme-linked immunosorbent assay for quantitation of Haemophilus influenzae type B polysaccharide-specific IgG1 and IgG2 in human and infant rhesus monkey sera | |
| JPH11503525A (ja) | 単糖類、オリゴ糖類または多糖類を固相に結合させる方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |